hotspot -WSS

hotspot

author：explore 2025-10-02 11:10:44 - browse：615

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： How to save PrEP access — and even expand it
Next article： CDC concerned about possible undetected monkeypox spread in U.K.

entertainment

hotspot

WSS

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

STAT's guide to the next generation of CAR

Paxlovid study fails to answer questions over benefit for broader groups

WATCH: Why do fingernails fall off when they're damaged?

What would happen to your eyes if you looked at the solar eclipse?

The science behind Janet Jackson's pregnancy at 49

knowledge

hotspot

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Why psychiatrists like me stop taking insurance

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

With FDA staff opposed to Sarepta therapy, top official intervened

Jerome Adams on the need for new antivirals for Covid

In areas with more Black doctors, Black people live longer

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Morgan Health, with ambitious aims, wants you to know it’s still here

Drug repurposing or repositioning? The language matters

Why are elite athletes different? Take a look at their microbes

leisure time

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

J&J to buy cancer drug developer Ambrx Biopharma

3 trends to watch in health tech's hiring outlook for 2024

Paxlovid study fails to answer questions over benefit for broader groups

In areas with more Black doctors, Black people live longer

A single drug, study failures leave Anavex with nothing but cash

entertainment

hotspot

leisure time

entertainment